<code id='042064EAB2'></code><style id='042064EAB2'></style>
    • <acronym id='042064EAB2'></acronym>
      <center id='042064EAB2'><center id='042064EAB2'><tfoot id='042064EAB2'></tfoot></center><abbr id='042064EAB2'><dir id='042064EAB2'><tfoot id='042064EAB2'></tfoot><noframes id='042064EAB2'>

    • <optgroup id='042064EAB2'><strike id='042064EAB2'><sup id='042064EAB2'></sup></strike><code id='042064EAB2'></code></optgroup>
        1. <b id='042064EAB2'><label id='042064EAB2'><select id='042064EAB2'><dt id='042064EAB2'><span id='042064EAB2'></span></dt></select></label></b><u id='042064EAB2'></u>
          <i id='042064EAB2'><strike id='042064EAB2'><tt id='042064EAB2'><pre id='042064EAB2'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:896
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Argenx readies a blockbuster opportunity with drug for autoimmune disease
          Argenx readies a blockbuster opportunity with drug for autoimmune disease

          MollyFerguson/STATHaveyouheardthenews?I’mlaunchingaweeklyemailnewsletterstartingonMarch28.It’scalled

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Kaiser's Risant Health gobbled up Geisinger. Who is next?

          AdobeMorethanayearago,KaiserPermanentemadewaveswhenitsaiditwascreatinganew,sprawlingentityofnonprofi